A team reported Phase Ib results for a personalized neoantigen dendritic cell vaccine in newly diagnosed glioblastoma, with findings published in Nature Communications. The approach uses autologous dendritic cells pulsed with patient-specific neoantigens, targeting an aggressive brain tumor where durable immune control remains difficult. The story characterizes the trial as early but “promising,” positioning the therapy as part of a broader effort to make cancer vaccines more individualized. With glioblastoma, trial design details—such as immune response readouts, safety, and how responses correlate with neoantigen selection—will determine whether the platform can move toward larger studies. For industry, this readout adds incremental but notable evidence supporting personalized dendritic cell vaccination strategies in hard-to-treat solid tumors.